ACP
ADMA icon

Aviance Capital Partners’s ADMA Biologics ADMA Stock Holding History

Aviance Capital Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,863
Closed -$326K – 369
2025
Q4 		$326K Buy
17,863
+1,613
+10% +$27.2K 0.04% 294
2025
Q3 		$238K Buy
+16,250
New +$279K 0.03% 330
2024
Q4 		– Sell
-11,450
Closed -$229K – 323
2024
Q3 		$229K Buy
+11,450
New +$178K 0.03% 306

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Aviance Capital Partners's ADMA Position: Q1 2026 in Review

Aviance Capital Partners sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 17,863 shares — an estimated $326K sold.

Aviance Capital Partners first reported a position in ADMA in Q3 2024 and held it in 3 quarters. The position peaked at $326K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Aviance Capital Partners reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Aviance Capital Partners sold 17,863 ADMA Biologics shares in Q1 2026, an estimated $326K.
  • Aviance Capital Partners first reported a position in ADMA Biologics in Q3 2024 and held it in 3 quarters.
  • Aviance Capital Partners's ADMA Biologics position peaked at $326K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Aviance Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.